Last reviewed · How we verify
BMS-562086
At a glance
| Generic name | BMS-562086 |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pexacerfont to Reduce Stress-induced Tobacco Craving
- Pexacerfont for Stress-induced Food Craving (EARLY_PHASE1)
- Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^ (PHASE2)
- Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder (PHASE2, PHASE3)
- Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder (PHASE1, PHASE2)
- A Study of BMS-562086 in Patients With Irritable Bowel Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMS-562086 CI brief — competitive landscape report
- BMS-562086 updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI